Table 4.

Patient characteristics

Controls (n = 1,126)Cases (n = 591)
NSABP Trial
 P1138 (12.3%)79 (13.4%)
 P2988 (87.7%)512 (86.6%)
Type of breast event
 Invasive breast cancer0 (0%)452 (76.5%)
 DCIS0 (0%)139 (23.5%)
Treatment
 Tamoxifen595 (52.8%)318 (53.8%)
 Raloxifene531 (47.2%)273 (46.2%)
Age (y) at entry
 Mean (SD)59.9 (7.30)59.9 (7.28)
 Median59.059.0
 <55276 (24.5%)146 (24.7%)
 55–59327 (29%)170 (28.8%)
 60–64252 (22.4%)136 (23%)
 65+271 (24.1%)139 (23.5%)
5-year predicted breast cancer risk
 Mean (SD)4.8 (2.40)4.9 (2.50)
 Median4.24.5
 < = 2.00%63 (5.6%)33 (5.6%)
 2.01%–3.00%236 (21%)121 (20.5%)
 3.01%–5.00%349 (31%)183 (31%)
 >5.00%478 (42.5%)254 (43%)
History of LCIS at entry
 No918 (81.5%)479 (81%)
 Yes208 (18.5%)112 (19%)
History of Atypical Hyperplasia at entry
 No863 (76.6%)435 (73.6%)
 Yes263 (23.4%)156 (26.4%)
Number of first-degree relatives with breast cancer
 0338 (30%)198 (33.5%)
 1544 (48.3%)268 (45.3%)
 2+244 (21.7%)125 (21.2%)
Time (months) on tamoxifen or raloxifene
 Mean (SD)47.2 (18.78)29.5 (20.30)
 Median60.027.5